Viewing Study NCT02418923


Ignite Creation Date: 2025-12-18 @ 8:21 AM
Ignite Modification Date: 2025-12-18 @ 8:21 AM
Study NCT ID: NCT02418923
Status: None
Last Update Posted: 2016-05-11 00:00:00
First Post: 2015-04-13 00:00:00
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: HemoSonics-UVA Spinal Surgery
Sponsor: None
Organization:

Study Overview

Official Title: HemoSonics-UVA Spinal Surgery Clinical Study Protocol
Status: None
Status Verified Date: 2016-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: HemoSonics is developing a novel POC diagnostic device, the Quantra System, to perform whole blood coagulation analysis and which is suitable for use in surgical and intensive care settings. The Quantra System employs a patented technology named sonorheometry, which was invented at the University of Virginia.

Sonorheometry uses ultrasound pulses to characterize the dynamic changes in viscoelastic properties of a blood sample during coagulation and clot lysis. The initial assay performed on the Quantra System will be the surgical assay for monitoring hemostasis during major surgical procedures in adult patients.

A clinical study will be conducted to evaluate the analytical performance as well as compared to existing coagulation monitoring technology
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: